Ritodrine Hydrochloride: A Betamimetic Agent for Use in Preterm Labor. II. Evidence Of Efficacy
Ritodrine Hydrochloride: A Betamimetic Agent for Use in Preterm Labor. II. Evidence Of Efficacy
复制标题
盐酸利托君：一种用于早产的β受体激动剂。
作者：
I. Merkatz;J. Peter;T. Barden
在多中心随机前瞻性双盲对照研究中，比较了盐酸利托君与乙醇或安慰剂治疗特发性早产的疗效。与对照组相比，利托君治疗组母亲的后代中新生儿死亡和呼吸窘迫综合征的发生率显著降低（两组比较P<0.05），达到妊娠36周（P<0.05）或出生体重大于2500 g（P<0.05）的婴儿比例显著较高。与对照组相比，利托君治疗组分娩时的胎龄（P<0.05）和子宫内天数（P<0.001）也有显著改善。这些结果，加上普遍可接受的副作用，使利托君成为美国第一个批准用于治疗早产的药物
In a multicenter series of randomized prospective doubleblind controlled studies, ritodrine hydrochloride was compared with either ethanol or placebo in treatment of idiopathic preterm labor. When compared with controls, there was, among offspring of ritodrine-treated mothers, a significantly reduced incidence of neonatal death and respiratory distress syndrome (P<.05 in both comparisons) and a significantly higher proportion of infants achieving 36 weeks' gestation (P<.05) or birth weight greater than 2500 g (P<.05). There was also a significant improvement in gestational age at delivery (P<.05) and in the number of days gained in utero (P<.001) among ritodrine-treated patients as compared with controls. These results, coupled with a finding of generally acceptable side effects, have contributed to ritodrine's becoming the first drug approved for the treatment of preterm labor in the United States